MOCS2

Across TCGA pan-cancer cohorts, MOCS2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MOCS2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MOCS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MOCS2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where MOCS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.514	0.313	<.001	62	view →
HNSC	DFS	Quartile	III,IV	0.900	0.634	.016	18	view →
UCEC	DFS	Quartile	All	0.960	0.758	.020	8	view →
LUAD	DFS	Tertile	II,III,IV	0.752	0.924	.027	8	view →
CCRCC	DFS	Tertile	III,IV	0.904	0.125	.024	4	view →
LSCC	DFS	Tertile	All	0.810	1.000	.012	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MOCS2–PDAC (DFS)

Open the PDAC breakdown →